Discounted Cash Flow Rating

Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Rogers Corporation (ROG)

Plastic Materials, Synth Resins & Nonvulcan Elastomers

https://www.rogerscorp.com

Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: advanced connectivity solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and power electronics solutions, which sells ceramic substrate materials for power module applications. The firm generates revenue primarily in the United States, China, and Germany, but has a presence around the world.

2225 W CHANDLER BLVD
CHANDLER, AZ

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/17/1980

Market Cap

1,977,177,598

Shares Outstanding

18,620,000

Weighted SO

18,616,519

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

Beta

0.5360

Last Div

0.0000

Range

100.31-148.11

Chg

-0.7467

Avg Vol

167443

Mkt Cap

1977177598

Exch

NYSE

Country

US

Phone

480 917 6000

DCF Diff

-41.2556

DCF

147.8196

Div Yield

0.0000

P/S

2.2954

EV Multiple

17.7492

P/FV

1.5682

Div Yield %

0.0000

P/E

34.0077

PEG

42.1856

Payout

0.0000

Current Ratio

4.3099

Quick Ratio

3.0155

Cash Ratio

1.0292

DSO

83.0135

DIO

96.1788

Op Cycle

179.1923

DPO

31.8258

CCC

147.3666

Gross Margin

0.3356

Op Margin

0.0953

Pretax Margin

0.0909

Net Margin

0.0675

Eff Tax Rate

0.2575

ROA

0.0391

ROE

0.0466

ROCE

0.0599

NI/EBT

0.7426

EBT/EBIT

0.9534

EBIT/Rev

0.0953

Debt Ratio

0.0129

D/E

0.0152

LT Debt/Cap

0.0118

Total Debt/Cap

0.0150

Int Coverage

-25.4405

CF/Debt

8.6771

Equity Multi

1.1795

Rec Turnover

4.3969

Pay Turnover

11.4687

Inv Turnover

3.7950

FA Turnover

2.2472

Asset Turnover

0.5792

OCF/Share

8.9570

FCF/Share

6.1281

Cash/Share

6.4462

OCF/Sales

0.1934

FCF/OCF

0.6842

CF Coverage

8.6771

ST Coverage

40.6344

CapEx Coverage

3.1662

Div&CapEx Cov

3.1662

P/BV

1.5682

P/B

1.5682

P/S

2.2954

P/E

34.0077

P/FCF

17.3464

P/OCF

11.8681

P/CF

11.8681

PEG

42.1856

P/S

2.2954

EV Multiple

17.7492

P/FV

1.5682

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 07, 02:00 Competing for Rogers $1M Prize: Canada’s Got Talent Reveals the First Six Performers Heading to the Finale, May 13 on Citytv GlobeNewswire Inc. May 07, 02:00 En compétition pour remporter le prix de 1 M$ offert par Rogers : Canada’s Got Talent dévoile les six premiers artistes à se rendre à la finale diffusée le 13 mai sur Citytv GlobeNewswire Inc. Nov 12, 02:00 JFROG ALERT: Bragar Eagel & Squire, P.C. is Investigating JFrog Ltd. on Behalf of JFrog Stockholders and Encourages Investors to Contact the Firm The Motley Fool Oct 11, 23:16 Why JFrog Stock Flew Nearly 5% Higher on Friday Zacks Investment Research Aug 09, 00:30 JFrog (FROG) Reports Q2 Earnings: What Key Metrics Have to Say GlobeNewswire Inc. Jun 27, 05:00 Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection GlobeNewswire Inc. Jun 25, 05:00 Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis GlobeNewswire Inc. Jun 24, 05:00 Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories GlobeNewswire Inc. Jun 20, 05:00 Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma GlobeNewswire Inc. Jun 15, 14:00 Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma GlobeNewswire Inc. Jun 10, 05:05 Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization GlobeNewswire Inc. Jun 10, 05:00 European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer GlobeNewswire Inc. May 29, 05:00 FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation GlobeNewswire Inc. May 27, 05:00 Wechsel in der erweiterten Konzernleitung von Roche GlobeNewswire Inc. May 27, 05:00 Changes to the Roche Enlarged Corporate Executive Committee GlobeNewswire Inc. May 22, 05:00 Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk GlobeNewswire Inc. May 21, 05:00 FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation GlobeNewswire Inc. Mar 26, 16:45 Roche receives FDA approval for the first molecular test to screen for malaria in blood donors GlobeNewswire Inc. Mar 26, 16:45 Roche receives FDA approval for the first molecular test to screen for malaria in blood donors GlobeNewswire Inc. Mar 26, 16:45 Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.01 01/09/1992 11/30/-0001 01/15/1992 02/12/1992
0.01 10/09/1991 11/30/-0001 10/16/1991 11/14/1991
0.01 07/12/1991 11/30/-0001 07/18/1991 08/14/1991
0.01 04/11/1991 11/30/-0001 04/17/1991 05/16/1991
0.01 01/09/1991 11/30/-0001 01/15/1991 02/15/1991
0.01 10/16/1990 10/11/1990 10/22/1990 11/15/1990
0.01 07/10/1990 06/15/1990 07/16/1990 08/15/1990
0.01 04/10/1990 04/02/1990 04/17/1990 05/15/1990
0.01 01/09/1990 12/18/1989 01/16/1990 02/15/1990